Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) is a clinical-stage pharmaceutical company centered on developing orexin receptor 2 (OX2R) agonist therapies for sleep–wake and neuroscience-related disorders. The CNTA news feed highlights company announcements that track the progress of this multi-asset OX2R pipeline and related corporate developments.
Investors and followers of Centessa can use this page to review news about the Phase 2a CRYSTAL‑1 study of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as updates on the Phase 1 program for ORX142 in healthy volunteers and IND-enabling work for ORX489 in neuropsychiatric disorders. The company’s releases also describe preclinical data on additional OX2R agonists, including findings in animal models relevant to neuropsychiatric indications.
Beyond clinical milestones, CNTA news items cover capital markets and corporate events such as public offerings of American Depositary Shares, at-the-market sales agreements, participation in healthcare and investor conferences, and leadership changes reported via press release and Form 8‑K. These disclosures provide context on how Centessa funds and organizes its development activities.
This news page aggregates official communications from Centessa and related SEC-reported events, allowing readers to follow clinical data readouts, regulatory milestones like IND clearance, financing transactions and strategic updates around the company’s orexin-focused franchise. For ongoing research into CNTA, this stream offers a centralized view of the company’s reported progress and key announcements over time.
Full-Life Technologies announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer on January 16, 2023. Dr. Heeger brings over 15 years of experience in oncology clinical development, playing a key role in the development of Erbitux and leading successful clinical trials for various monoclonal antibodies. Dr. Liu, a peptide chemist, previously served as Head of Chemistry at Novo Nordisk and co-founded Focus-X, enhancing Full-Life's capabilities in radiopharmaceuticals. Both leaders are expected to accelerate the entry of targeted radiopharmaceuticals into clinical trials.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported promising long-term results for SerpinPC, an experimental treatment for hemophilia B, during the American Society of Hematology (ASH) Annual Meeting. The open-label extension (OLE) study revealed a 93% reduction in annualized bleed rates (ABR) for all bleeds and spontaneous joint bleeds at the highest dose. Importantly, no thromboembolic events or serious adverse effects were observed. The pivotal PRESent-5 study is set to commence soon, aiming to expedite SerpinPC's regulatory approval for patients with hemophilia B.
Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Karen Anderson as its new Chief People Officer, a role aimed at enhancing the company’s human resources and culture strategy. With over 25 years of experience in HR across biotechnology and pharmaceuticals, Anderson previously served as Chief Human Resources Officer at Mimecast and held senior positions at Alnylam Pharmaceuticals and Pfizer. CEO Saurabh Saha emphasized Anderson's strong track record in building high-performing teams, aligning with Centessa’s mission to develop transformational medicines for patients.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported its third-quarter financial results, highlighting a cash position of $444.8 million as of September 30, 2022, ensuring operational funding into 2026. The company announced three significant milestones: the advancement of the pivotal program for SerpinPC in hemophilia B with the initiation of PRESent-5, an upcoming ASH presentation on December 10, 2022, for 18-month data on SerpinPC, and an IND submission for LB101 planned for late 2022. R&D expenses increased to $36.7 million from $25.9 million year-over-year.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced new efficacy and safety data from an 18-month treatment with SerpinPC in hemophilia patients, set for oral presentation at the 64th American Society of Hematology Annual Meeting in December 2022. The Phase 2a study shows a significant reduction in annualized bleeding rates, with data supporting SerpinPC's potential as a safe subcutaneous treatment option. The study highlights a dosing regimen of 60 mg every 4 weeks followed by 1.2 mg/kg bi-weekly, with positive tolerability results.
Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences. The first event is the Jefferies London Healthcare Conference on November 17, 2022, featuring a fireside chat at 10:55 AM GMT. The second is the Evercore ISI HealthCONx Conference, held virtually on November 30, 2022, at 3:30 PM ET.
Live webcasts and archived recordings will be accessible on the Centessa Pharmaceuticals investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that its oral orexin receptor 2 (OX2R) agonists showed potent efficacy in non-clinical models of narcolepsy type 1 (NT1). The findings will be presented at the Sleep Europe 2022 conference. The OX2R agonists demonstrated more than a thousand-fold selectivity for OX2R over OX1R and were effective in promoting wakefulness and reducing cataplexy in model mice. Centessa emphasizes its commitment to developing treatments for narcolepsy and acknowledges World Narcolepsy Day on September 22.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that the FDA has granted Orphan Drug Designation for its drug candidate SerpinPC, aimed at treating hemophilia B. Registrational studies are set to commence in 4Q 2022. SerpinPC, designed to enhance thrombin generation, showed promising results in a Phase 2a study, demonstrating an 88% reduction in Annualized Bleeding Rate (ABR). The company also plans to release two-year follow-up data from the Phase 2a study in 4Q 2022, emphasizing the need for innovative treatment options.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive non-clinical pharmacokinetic and safety data for LB101, its first LockBody® candidate targeting solid tumors. The study showed systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, indicating an improved therapeutic index and enhanced anti-tumor activity. The company plans to submit an Investigational New Drug (IND) application by late 2022, with management discussing the findings at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in key investor conferences in September 2022. Notably, they will feature in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, with a fireside chat at 8:45 AM ET in New York City. Following this, they will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 PM ET. Lastly, they will engage in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 11:30 AM ET. Live webcasts will be available on their website.
FAQ
What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?
What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?
